Thoughts on this? >> Ardelyx sues Medicare over attempt to change coverage for dialysis drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #healthcare #productmarketing
LucidQuest’s Post
More Relevant Posts
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Ardelyx sues Medicare over attempt to change coverage for dialysis drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #healthcare #productmarketing
Ardelyx sues Medicare over attempt to change coverage for dialysis drug
https://endpts.com
To view or add a comment, sign in
-
Public Policy Update from CMSA! The Senate Finance Committee is taking action to address drug shortages by exploring reforms to Medicare and Medicaid programs. Read the "Preventing and Mitigating Drug Shortages" position paper to learn more about their proposed solutions: 🔗https://lnkd.in/eD9CaXK5 #CMSAPublicPolicy #HealthcareReform #DrugShortages #Medicare #SenateFinanceCommittee #CMSA #CaseManagement
https://www.finance.senate.gov/imo/media/doc/white_paper_preventing_drug_shortages.pdf
finance.senate.gov
To view or add a comment, sign in
-
“The Increasing Access to Biosimilars Act would take a critical step toward enhancing patient access to biosimilars through the creation of a voluntary shared savings demonstration program in Medicare Part B,” said Christine Simmon, executive director of the Biosimilars Council, in a 2021 statement about the bill. “The Biosimilars Council thanks Senator Michael Bennet and Senator John Cornyn for introducing this innovative solution to encourage greater biosimilar adoption and use in the US.” If passed, the HHS Secretary will implement a 3-year demonstration project that will check if offering a special payment can encourage doctors to prescribe more biosimilars for Medicare beneficiaries. Doctors will have a choice of whether to participate, and they would be able to withdraw from the project at any time. The Secretary would also have power to remove a doctor from the project if necessary. For the doctors who choose to participate, they will receive extra payments for prescribing more biosimilars instead of originators; however, the extra payment won’t increase out-of-pocket costs for patients. After the 3 years, the Secretary will report to Congress about how well the project is functioning. Congress will then have a choice of whether to extend or expand the project.
Medication costs causing you pain? Senators Bennet (D-CO) and Cornyn (R-TX) are fighting to make lifesaving treatments more affordable with the Increasing Access to Biosimilars Act. 🚩 Click the link to understand what this bill could mean for patients https://lnkd.in/dHN5GWQr
Senators Reintroduce the Increasing Access to Biosimilars Act
centerforbiosimilars.com
To view or add a comment, sign in
-
A KFF analysis shows that a new out-of-pocket spending cap in Medicare Part D could translate into savings for well over 1 million beneficiaries when it takes effect next year, including more than 100,000 people each in California, Florida and Texas, based on analyses of drug spending in 2021. To read more, go to https://lnkd.in/eRP4FGf7 #medicare #PartD #prescriptiondrugs
New $2,000 Medicare Part D Cap Could Reduce Out-of-Pocket Drug Costs Beginning Next Year
https://ohiohealthbenefits.net
To view or add a comment, sign in
-
🌟 Another Week, Another Weekly Wrap-Up! 🌟 As we close another week in the healthcare industry, it's time to take a brief look back at the significant developments that are shaping our sector. This week's highlights include innovative breakthroughs, impactful collaborations, and progressive regulatory updates that continue to drive commitments to improving patient care and enhancing health solutions worldwide. From groundbreaking research findings to strategic partnerships that promise to elevate patient outcomes, our weekly wrap-up has it covered for you. #Healthcare #Pharma #Biotech #HealthcareNews #Innovation Check out the latest happenings with Amgen, TriLink BioTechnologies, part of Maravai LifeSciences, Cedars-Sinai, FDA, Apple, Regeneron, and More. 👇
Healthcare Industry News Weekly Wrap-Up: May 9, 2024
https://vaultbio.com
To view or add a comment, sign in
-
In 2022, over 20% of adults age 65+ could not afford their prescription medications. LINET, which is administered exclusively by Humana, helps by providing temporary, short-term cost relief for certain #Medicare beneficiaries not enrolled in a drug plan. Learn more about this program, what it covers, and who is eligible for assistance.👇 #MedicareAnniversary https://lnkd.in/eMgpUFrb
Do I Qualify for LI NET Prescription Drug Coverage?
ncoa.org
To view or add a comment, sign in
-
#prescriptiondrugpricing is front and center in the #healthpolicy debate with strongly held views on both sides of the isle. It is particularly pressing for #raredisease #policy given the often high list prices and persistent large unmet medical need. The reality is that #drugpricing is an extremely complex topic, and one that requires nuanced policy solutions to balance availability and access - and it is one that ultimately impacts each and every one of us in deeply personal ways. Kudos to STAT for trying to untangle this thorny issue and make it more understandable for a broad audience. One issue that is too often lost in the debate: there is no neat 1:1 correlation between list prices (where most of the policy debate is focused) and actual out-of-pocket costs for families. That is why incorporating patient perspectives in this discussion, from #inflationreductionact #IRA to #prescriptiondrugaffordabilityboards #PDABs and beyond is so important! Watch the videos here: https://lnkd.in/en5_ig88
The role of PBMs, patents, and public health in drug pricing
https://www.statnews.com
To view or add a comment, sign in
-
Drug Affordability and Access will be a Key Priority for States. #patientaccess #patientaffordability #marketaccess #healthcarepolicy https://lnkd.in/ezD5EKgg
States Will Prioritize Drug Affordability and Access in 2024 | Avalere
https://avalere.com
To view or add a comment, sign in
-
Want to explore the latest state actions on today's biggest health policy challenges? Our interactive state trackers provide an overview of state activities on topics such as opioid settlements, prescription drug costs, Medicaid postpartum coverage, COVID-19, and more. Check it out: https://loom.ly/ZHWKq-U
To view or add a comment, sign in
-
Get key insight from the #MyMatrixx clinical team on best practices and guidance to help keep injured workers and their families safe when it comes to medication disposal: https://bit.ly/3Q8sYgn
Promoting Safety for Injured Workers and their Families | myMatrixx
mymatrixx.com
To view or add a comment, sign in
6,232 followers